المصدر: Reactions Weekly; 6/22/2024, Vol. 2013 Issue 1, p8-8, 1p

مصطلحات موضوعية: OLDER people, MEDICAL personnel, MEDICAL equipment

مستخلص: According to an article in the June 2024 issue of Prescriber Update, older people are at an increased risk of medicine-induced hyponatraemia. This was highlighted after a severe case of hyponatraemia was reported in an older person who had recently started taking a selective serotonin-reuptake inhibitor (SSRI) and was also taking furosemide. A review of reports in New Zealand showed that between January 2000 and December 2023, 288 cases of hyponatraemia were reported to the New Zealand Medicines and Medical Devices Safety Authority. Of these, 208 cases were in people aged over 65. The most commonly reported suspect medicines for hyponatraemia in this age group were antidepressants, diuretics, and the proton-pump inhibitor omeprazole. Healthcare professionals are advised to use caution when prescribing medicines known to cause hyponatraemia in the elderly, consider lower doses or alternative treatments, and monitor plasma sodium levels before and during treatment. If medicine-induced hyponatraemia occurs, the patient's plasma sodium levels should be managed and the suspected medicine stopped if necessary. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; 6/22/2024, Vol. 2013 Issue 1, p7-7, 1p

مصطلحات موضوعية: LAMOTRIGINE, HOMOGENEITY, MEDICAL personnel

مستخلص: Desitin Pharma UK is recalling all batches of Lamotrigine Desitin 10mg/ml Oral Suspension as a precautionary measure due to a potential homogeneity issue. This issue could result in doses containing too little or too much of the active ingredient, leading to underdosing or overdosing. While there have been no confirmed reports of this occurring, healthcare professionals are advised to stop supplying the impacted batches and patients should not stop their medication. Alternative forms of lamotrigine treatment may be necessary, as there are no other licensed oral suspension/solutions available. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; 6/22/2024, Vol. 2013 Issue 1, p2-2, 1p

مصطلحات موضوعية: DRUGS, MEDICAL personnel, DRUG overdose

مستخلص: The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has approved cold and flu medicines containing pseudoephedrine, which had not been available in New Zealand for several years. Pseudoephedrine is used to relieve symptoms such as nasal congestion and rhinorrhea, and is often combined with other ingredients like paracetamol or ibuprofen. Healthcare professionals are advised to caution patients against using multiple cold and flu medicines simultaneously to avoid accidental overdose, and to not exceed the recommended dose. Pseudoephedrine should not be used by patients with certain medical conditions or allergies, and may cause side effects such as sleeplessness, skin reactions, or vision problems. These medicines are classified as pharmacist-only in New Zealand. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; 6/8/2024, Vol. 2011 Issue 1, p193-193, 1p

مصطلحات موضوعية: DRUG overdose, MEDICATION errors, METHOTREXATE, MEDICAL personnel, CHRONIC kidney failure

مستخلص: This article discusses various cases of toxicities and lack of efficacy associated with methotrexate overdose and medication errors. The cases include patients who experienced drug intoxication, leucopenia, thrombocytopaenia, aggravated skin lesions, stomatitis, pancytopenia, liver failure, kidney failure, bone marrow aplasia, and pulmonary infarction. One patient also exhibited lack of efficacy during treatment with folinic-acid and unspecified granulocyte-colony-stimulating-factors. The cases highlight the importance of proper medication administration and dosage instructions to prevent adverse reactions and improve patient outcomes. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; 6/8/2024, Vol. 2011 Issue 1, p5-5, 1p

مصطلحات موضوعية: SUGAMMADEX, ALLERGIES, ROCURONIUM bromide, MEDICAL personnel, MUSCLE relaxants

مستخلص: A recent report from the Netherlands Side Effects Center Lareb highlights the potential for a severe allergic reaction when the muscle relaxant effects of rocuronium are stopped using sugammadex. This reaction can occur even in patients who are not individually allergic to either drug. The package leaflets for both drugs mention the possibility of an allergic reaction, but do not specifically mention the potential for a reaction to the sugammadex-rocuronium complex. Lareb recommends testing for hypersensitivity to the complex in order to prevent future allergic reactions. The report has been shared with healthcare providers by Lareb and the Medicines Evaluation Board. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; 6/8/2024, Vol. 2011 Issue 1, p4-4, 1p

مصطلحات موضوعية: STEROIDS, REPORT cards, MEDICAL personnel

مستخلص: The UK Medicines and Healthcare products Regulatory Agency (MHRA) is advising that topical corticosteroid products will be labeled with information on their potency to prevent the risks of topical steroid withdrawal (TSW) reactions. TSW reactions have been reported after long-term use of moderate or stronger potency topical corticosteroids, particularly for eczema treatment. These reactions can include redness, stinging, and burning of the skin, and the risk is higher with prolonged use of higher potency corticosteroids. Topical corticosteroids will be labeled with potency information to assist with patient counseling, and healthcare professionals should consider alternative treatments if previous corticosteroid discontinuation was associated with TSW reactions. Patients should seek medical advice before using a topical steroid on a new body area, and they should always follow instructions and read the Patient Information Leaflet. Mild, moderate, strong, and very strong steroids will be labeled accordingly. TSW reactions are estimated to be rare based on available data. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; 6/8/2024, Vol. 2011 Issue 1, p2-2, 1p

مصطلحات موضوعية: MEDICAL personnel

مستخلص: Health Canada has updated the Canadian product monograph for lisdexamfetamine (Vyvanse) to include a warning about the risk of heart rate-corrected QT (QTc)-interval prolongation. Healthcare professionals are advised to use caution when prescribing lisdexamfetamine to patients with a prolonged QTc interval, those taking other drugs that affect the QTc interval, and those with pre-existing cardiac disease or electrolyte disturbances. Vyvanse is contraindicated in patients with symptomatic cardiovascular disease and moderate to severe hypertension. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; May2024, Vol. 2009, p5-5, 1p

مصطلحات موضوعية: GLATIRAMER acetate, MEDICATION errors, MEDICAL personnel, ACETATES

مستخلص: The US FDA has issued a warning about the risk of medication errors when using incompatible autoinjectors for glatiramer acetate injection products. Using an autoinjector that is not compatible with a specific glatiramer acetate injection product can lead to missed doses or partial doses. Some glatiramer acetate injection products can be administered using an optional compatible autoinjector, while others must only be injected using a prefilled syringe. Patients are advised to confirm the compatibility of their autoinjector by consulting their healthcare professional, visiting the drug manufacturer's patient information website, contacting the drug manufacturer, or referring to the autoinjector labeling. It is important for patients to confirm compatibility each time they receive a new prescription for a glatiramer acetate injection product. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; May2024, Vol. 2009, p4-4, 1p

مصطلحات موضوعية: PROMETHAZINE, MEDICAL personnel

مستخلص: Oral promethazine products are now considered unsafe for children under 6 years of age, according to the New Zealand Medicines and Medical Devices Safety Authority (Medsafe). This decision was made after a safety review by the manufacturer, Sanofi, revealed a link between promethazine and psychiatric and CNS disorders in children aged 2-5. The data sheets and consumer medicines information for affected products have been updated, and healthcare professionals are advised to consult with a pharmacist or doctor for alternative treatment options for young children. Consumers and caregivers should be aware that promethazine may cause mood and behavioral changes, as well as learning difficulties at high doses in children under 6. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المصدر: Reactions Weekly; May2024, Vol. 2009, p3-3, 1p

مصطلحات موضوعية: AUTOIMMUNE hepatitis, DISEASE risk factors, MEDICAL personnel, LIVER failure

مستخلص: The Malaysian National Pharmaceutical Regulatory Agency (NPRA) has updated the labeling of olmesartan, a medication used to treat high blood pressure, to include the risk of autoimmune hepatitis. The European Medicines Agency (EMA) previously concluded that there is a plausible link between olmesartan and autoimmune hepatitis, and required an update to product information in January 2022. While the NPRA has received reports of adverse events related to olmesartan, including one case of acute hepatitis, no local cases of autoimmune hepatitis have been reported. Healthcare professionals are advised to be aware of the potential risk and to monitor patients for symptoms of autoimmune hepatitis. The NPRA has directed all registration holders of olmesartan-containing products to update package inserts and consumer medication information leaflets to reflect this safety information. [Extracted from the article]

: Copyright of Reactions Weekly is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)